PCSA on Nasdaq

Processa Pharmaceuticals, Inc.

American pharmaceutical preparations company based in Vero Beach. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with ZIOPHARM Oncology, One World Products, Inc. or Aspire-Lakewood Holdings, Inc., or pick any stock.

  • TickerPCSA on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersVero Beach, United States2
  • Incorporated inDE3
  • Business address601 21St Street, Suite 300, Vero Beach, Fl 329603
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI529900A51HZIE4XJB9602
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressc/o National Registered Agents, Inc.,1209 Orange Street, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 49610942

See how the biggest companies compare on our leaderboards

(“NGC”) small molecules, one of which is currently in a Phase 2 trial, while the other is in pre-clinical development.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-367.1%Return on equity5

Financial statements

Revenue67$0 in 2022
02021: $0$020212022: $0$02022
Operating income8679-$27.5M in 2022+599% since 2019
-$30.0M-$20.0M-$10.0M02019: -$3.9M-$3.9M20192020: -$15.1M-$15.1M2020+285%2021: -$12.1M-$12.1M2021−20%2022: -$27.5M-$27.5M2022+127%
Net income8679-$27.4M in 2022+717% since 2019
-$30.0M-$20.0M-$10.0M02019: -$3.4M-$3.4M20192020: -$14.4M-$14.4M2020+329%2021: -$11.4M-$11.4M2021−21%2022: -$27.4M-$27.4M2022+140%

Every line of the income statement as filed: the last 2 fiscal years, latest first.12

Period ending2025-12-312024-12-31
Research and development expenses$7.8M$7.3M
General and administrative expenses$6.2M$4.8M
Operating Loss-$14.0M-$12.1M
Other income$20.0K
Unrealized gain on digital assets at fair value$295.2K
Interest and dividend income, net$109.5K$201.1K
Net Operating Loss Before Income Tax Benefit-$13.6M-$11.9M
Net Loss-$13.6M-$11.9M
Net Loss Per Common Share - Basic-$10.36-$96.78
Net Loss Per Common Share - Diluted-$10.36-$96.78
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic1.3M shares122.4K shares
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted1.3M shares122.4K shares

Compare Processa Pharmaceuticals, Inc. with another company

Leadership

Who has led Processa Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. George K. Ng2023–now

Chief financial officer

  1. James H. Stanker2020–2024
  2. Russell Skibsted2024–now

Chief operating officer

  1. Robert Michael Floyd2020–2023
2025
Board members and other officers (10)

Former names

  • Heatwurx, Inc.Oct 28, 2011 to Oct 20, 20173

Timeline

  1. Aug 9, 2023New chief executive George K. Ng becomes CEO13
  2. Mar 29, 2011Founded Processa Pharmaceuticals, Inc. is founded2

Filings

423 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 77 major events, 246 insider forms, 14 large holders, 64 other. The latest 20:

  1. Oct 9, 2026PRE 14A EDGAR
  2. Oct 9, 2026PRE 14A EDGAR
  3. Oct 9, 2026S-3 EDGAR
  4. Oct 5, 20268-K/A EDGAR
  5. Aug 18, 2026SCHEDULE 13G EDGAR
  6. Aug 14, 202610-Q EDGAR
  7. Aug 11, 20264 EDGAR
  8. Aug 4, 20268-K EDGAR
  9. Jul 30, 20264 EDGAR
  10. Jul 30, 20263 EDGAR
  11. Jul 29, 20268-K EDGAR
  12. Jul 28, 20264 EDGAR
  13. Jul 28, 20264 EDGAR
  14. Jul 28, 20264 EDGAR
  15. Jul 28, 20264 EDGAR
  16. Jul 28, 20264 EDGAR
  17. Jul 28, 20264 EDGAR
  18. Jul 28, 20264 EDGAR
  19. Jul 28, 20264 EDGAR
  20. Jul 1, 20264 EDGAR

The 423 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

69 open-market trades by officers, directors and large owners since October 2021: 66 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 1, 2026Ng George KChief Executive OfficerBuy3,057$1.93$5.9KForm 4
Jun 30, 2026Guy WendyChief Administrative OfficerBuy2,436$1.93$4.7KForm 4
Jun 30, 2026Lin PatrickChief Business - Strategy OffBuy2,106$1.93$4.1KForm 4
Jun 30, 2026SKIBSTED RUSSELLChief Financial OfficerBuy3,277$1.93$6.3KForm 4
Jun 30, 2026Young DavidPres. Research & DevelopmentBuy2,531$1.93$4.9KForm 4
Jun 15, 2026Young DavidPres. Research & DevelopmentBuy2,067$2.22$4.6KForm 4
Jun 15, 2026SKIBSTED RUSSELLChief Financial OfficerBuy2,654$2.22$5.9KForm 4
Jun 15, 2026Ng George KChief Executive OfficerBuy2,465$2.22$5.5KForm 4
Jun 15, 2026Lin PatrickChief Business - Strategy OffBuy1,831$2.22$4.1KForm 4
Jun 15, 2026Guy WendyChief Administrative OfficerBuy2,118$2.22$4.7KForm 4
May 29, 2026Young DavidPres. Research & DevelopmentBuy1,786$2.57$4.6KForm 4
May 29, 2026SKIBSTED RUSSELLChief Financial OfficerBuy2,292$2.57$5.9KForm 4
May 29, 2026Ng George KChief Executive OfficerBuy2,129$2.57$5.5KForm 4
May 29, 2026Lin PatrickChief Business - Strategy OffBuy1,582$2.57$4.1KForm 4
May 29, 2026Guy WendyChief Administrative OfficerBuy1,829$2.57$4.7KForm 4
May 15, 2026Ng George KChief Executive OfficerBuy1,843$2.97$5.5KForm 4
May 15, 2026Young DavidPres. Research & DevelopmentBuy1,545$2.97$4.6KForm 4
May 15, 2026Lin PatrickChief Business - Strategy OffBuy1,369$2.97$4.1KForm 4
May 15, 2026Guy WendyChief Administrative OfficerBuy1,583$2.97$4.7KForm 4
May 15, 2026SKIBSTED RUSSELLChief Financial OfficerBuy1,984$2.97$5.9KForm 4

All 69 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Connective Capital Management, LLC85,274$163.7K0.1%+14,538
Stonepine Capital Management, LLC55,000$105.6K0.1%No change
Geode Capital Management, LLC22,090$42.4K0.0%−2,818
Citadel Advisors LLC21,306$40.9K0.0%New
StoneX Group Inc.11,437$29.6K0.0%New
XTX Topco Ltd13,292$25.5K0.0%New
Jane Street Group, LLC13,264$25.5K0.0%New
Vanguard Capital Management LLC12,729$24.4K0.0%No change
Vanguard Fiduciary Trust Co10,857$20.8K0.0%No change
UBS Group AG7,794$15.0K0.0%+5,263
Tower Research Capital LLC (TRC)2,499$4.8K0.0%+1,581
Jones Financial Companies Lllp7$130.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32